Overview

• The EMA’s Committee for Medicinal Products for Human Use has backed the use of a next-generation Honeywell propellant in the triple-drug Trixeo Aerosphere for COPD.
• Trials showed the new HFO-1234ze(E) gas delivers equivalent lung doses without additional safety risks and cuts global warming potential by up to 99.9%.
• If the European Commission follows EMA advice, Trixeo Aerosphere will be the first EU inhaler to deploy the low-carbon propellant in place of HFA-134a.
• AstraZeneca has commenced transitioning its European Trixeo supply based on the CHMP recommendation.
• The eco-friendly inhaler was the first of its kind to secure UK approval in May and is now under regulatory review in China.